Apogee Therapeutics saw its shares trade roughly 16% higher in pre-market Wednesday after the company disclosed a $1.3 billion financing collaboration with Blackstone Life Sciences aimed at advancing zumilokibart, its investigational treatment for atopic dermatitis.
The deal comprises two principal elements: up to $800 million structured as synthetic royalty funding and up to $500 million available as senior corporate debt, the company said. The debt portion is accessible only with mutual consent from both parties.
Under the agreement, Blackstone will receive tiered royalties, described as low-to-mid single digits, on worldwide annual sales of zumilokibart for a period of 15 years. The arrangement includes a carve-out so that no royalties are payable on global annual sales that exceed $8 billion.
The synthetic royalty component is broken into tranches tied to clinical and regulatory milestones. Apogee is slated to receive $100 million at signing, another $100 million upon completion of Phase 3 enrollment, and $200 million contingent on positive Phase 3 data. An additional $400 million becomes available upon FDA approval of the drug candidate, with $150 million of that amount exercisable at Apogee’s option.
Apogee noted that when combined with the company’s current cash balance of $1.3 billion, the financing package positions it to pursue commercialization of zumilokibart without the need to access equity markets for additional funding. In light of the transaction, the company removed its prior guidance on cash runway.
Context and market reaction
The market reaction was immediate, with the stock jumping in pre-market trading on the day the agreement was disclosed. Apogee framed the transaction as providing the capital structure necessary to support late-stage development and potential commercialization of its atopic dermatitis candidate while preserving future strategic optionality through the availability of senior debt only by mutual agreement.
What remains stated by the company
All financial commitments, milestone triggers, royalty terms and the company cash balance reported above come directly from Apogee’s announcement. The company’s decision to withdraw its previous cash runway guidance was explicitly linked to this new financing arrangement.